3 Undervalued UK ADRs Trading On The NYSE

Published Wed, 24 Feb 2016 20:45 CET by DividendYields.org

The London Stock Exchange offers value investors great stocks with strong fundamentals and a sustained dividend growth. However, with the currency exchange rates, it is often expensive for US investors to invest directly in the LSE. Through the ADRs - in this article American Depositary Receipts -, value investors can invest in foreign stocks that trade in the NYSE or the Nasdaq at the lowest cost.
Another thing to consider is whether a stock is over- or undervalued. This means that its market price is higher or lower than its present value. When a stock is overvalued and its market price is higher than its present value, investors should sell the stock as it is already more expensive than its actual value and it is highly unlikely to rise further. When a stock is undervalued and its market price is lower than its present value, investors should buy the stock as it is expected that it will rise further.
There are several methods to assess if a stock is over- or undervalued, the most popular being the Graham Number and the Dividend Discount Model (DDM). However, the Graham Number doesn’t take into consideration the dividend growth or other fundamentals of the company and thereby, it is not effective for mid and large-caps.
In this article we discuss three British ADRs, large caps of different sectors that trade on the NYSE. According to the Dividend Discount Model, all three are undervalued.

British American Tobacco, GlaxoSmithKline and Unilever YoY Stock Performance Graph
British American Tobacco (ADR) (NYSE: BTI) is a London-based tobacco manufacturer and seller that provides cigarettes, cigars, and a range of nicotine products, and electronic cigarettes worldwide. British American Tobacco operates under Benson & Hedges, Craven A., Dunhill, John Player Gold Leaf, Kent, Kool, Lucky Strike, Pall Mall, Peter Stuyvesant, Rothmans, State Express 555, Viceroy and Vogue brand names and sells its products in Europe, Asia-Pacific, the Americas, Africa and the Middle East.

Strong Fundamentals: British American Tobacco is a financially healthy company with strong fundamentals. In its Q3 2015 results, the company’s revenues grew 4.2% YoY without adjusting for currency fluctuation, mainly driven by sustained strong pricing and growth in low price segments. The revenue growth has led to an increase in cigarette market share by 40 basis points in primary growth regions like Australia, France, Indonesia, Japan, Malaysia, Pakistan, Russia, South Korea, Turkey, Ukraine and the UK.

Dividend Growth: British American Tobacco declares an annualized dividend of $3.09, yielding 2.81% at a payout ratio of 50%. Since 2000, the company has been consistently delivering a dividend, reaching a 146.5% dividend growth, or 9.8% annually. Considering a discount rate of 28%, the present value of the stock is $109.92 / (0.28 - 0.10) = $109.92 / 0.18 = $610.67. Since the present value is significantly higher than the market price, the stock is seen as undervalued.
The ADR enables investors to buy British American Tobacco stock at a price that is significantly cheaper than the trading price on the London Stock Exchange (LSE). Through the ADR, value investors can invest in a fundamentally strong company at a lower cost.

GlaxoSmithKline (ADR) (NYSE: GSK) is a Brentford-based developer, manufacturer, and seller of pharmaceutical products, including vaccines, over-the-counter medicines, and health-related consumer products worldwide. GlaxoSmithKline provides pharmaceutical products, consumer healthcare products in wellness, oral health, nutrition, and skin health areas and has collaboration agreements with Université de Sherbrooke and Pfizer; development and R&D collaboration with Propeller Health; R&D collaboration agreement with Valneva SE; and collaboration and license agreement with Idera pharmaceuticals.

Strong Fundamentals: In FY 2015 results, GlaxoSmithKline reported revenues $23.9 billion, down 9.5% YoY from $26.4 billion in FY 2014. On the upside, operating expenses were down 33.3% YoY, operating income was up 52.9% YoY and net income reached $8.4 billion, up 87.2% from 4.5 billion in the same period last year. In spite of the debt-to-equity ratio of 3.0, which is normal for a drug company since the pharmaceutical sector is highly capital-intensive, GlaxoSmithKline is a financially healthy company and a great pick for value investors.

Dividend Growth: GlaxoSmithKline declares an annualized dividend of $2.60, yielding 6.74% at a payout ratio of 54%. The company’s dividend growth since 2000 is 33.5% or 2.2% annually. Considering a discount rate of 25%, the present value of the stock is $39.76 / (0.28 - 0.02) = $39.76 / 0.26 = $152.92. Since the market price is lower than the present value, the stock is considered undervalued.

Name Price ($) 52 wk low 52 wk high 52 wk low % 52 wk high % Market Cap ($ b) P/E D/E Beta Payout Ratio
British American Tobacco 107.29 99.81 119.91 7.49% -10.52% 102.46 17.65 2.36 1.08 50%
GlaxoSmithKline 38.21 37.24 49.08 2.60% -22.15% 96.22 7.98 3.00 0.84 44%
Unilever 42.39 38.60 46.19 9.82% -8.23% 124.01 22.71 0.64 0.81 69%

Unilever (ADR) (NYSE: UL) is a London-headquartered consumer goods company with a large network in the Americas, Africa, Asia, Australia, Europe and the Middle East. Through its Personal Care, Foods, Refreshment, and Home Care segment, Unilever offers well-established brand names, including Axe, Dove, Lux, Rexona, and Sunsilk, Hellmann’s and Knorr, Ben & Jerry’s, Cif, Comfort, Domestos, Omo, Persil, and Surf, among others.

Strong Fundamentals: Compared to FY 2014, Unilever has reported strong FY 2015 results as follows:

  • Revenues $53.27 billion, up 3.8% YoY from $51.32 billion
  • Operating expenses up 3.2% YoY to $45.76 billion from $44.35 billion
  • Operating Income up 7.7% YoY to $7.52 billion from $6.98 billion
  • Net Income $4.91 billion, up 12.4% YoY from $4.37 billion

Dividend Growth: Since 2000, Unilever dividend growth is 16% or 1.1% annually. Currently, Unilever declares an annualized dividend of $1.32, yielding 3.02% at a payout ratio of 69%. Considering a discount rate of 25%, the present value of Unilever stock is $43.65 / (0.25 - 0.01) = $43.65 / 0.24 = $180.21. Given that the market price is lower than the present value, the stock is viewed as undervalued.


Stock name Dividend Yield
British American Tobacco 6.64
Glaxosmithkline 4.47
Unilever 2.95

Articles featuring British American Tobacco (BTI):

14 Great High-Yield Stocks For A Rich Retirement

Many people nearing retirement have a problem. The market is at all-time highs, is historically overvalued, and bond yields are near all-time lows. Over 10 years, 90% of bond returns are determined by starting yield, so future bond returns are likely to be very low, compared to their strong returns over the past 35 years. Similarly, 90% of long-term stock forward returns are determined by starting valuation, according to a study by Bank of America's quantitative analysts, and... Read more

A Balanced Look At Heavily Discounted Tobacco Stocks - Part 3: Imperial Brands PLC & Its 10%+ Yield

Source: Imperial Brands Unlike Altria Group, Inc. (MO), Imperial Brands PLC (OTCQX:IMBBY) derives most of its sales from Europe. Imperial didn't always yield ~10.5%; the stock has declined by approximately 60% since 2016's cyclical peak. 2018's cash dividends paid, however, are triple those of 2009. That's an incredible feat and a testament to the cash generating power of "Big Tobacco." Our longer-term subscribers and followers won't be surprised by what comes next: there is a catch. A... Read more

1 Of These 4 Dividend Stocks Is My Next Retirement Portfolio Buy This Earnings Season

Many readers have asked me why I am still buying so aggressively ahead of a possible recession. The answer is that my risk profile, based on my age, income, savings rate, and diversified income sources (39 in total, including dividend stocks) means I can focus on the long term and not worry about what happens with the economy over the next few years. Besides, right now, we're merely facing a slowdown in growth, with little chance of a recession in the next year. The bond market, via the... Read more

The Best Dividend Stocks To Buy Ahead Of The Next Fed Rate Cut

Due to reader requests, I've decided to break up my weekly "Best Dividend Stocks To Buy This Week" series into two parts. One will be the weekly watch list article (with the best ideas for new money at any given time). The other will be a portfolio update. To also make those more digestible, I'm breaking out the intro for the weekly series into a revised introduction and reference article on the 3 rules for using margin safely and profitably (which will no longer be included in those... Read more

98 Most Reliable Dividend Stocks On Earth: Kiplinger's International Aristocrats For Mid-October

Actionable Conclusions (1-10): Analysts Estimated 16.64% To 35.93% Net Gains For Ten Top International Dividend Aristocrat Dogs Into October 2020 Four of these ten top Kiplinger most reliable dividend stocks by yield were among the top ten gainers for the coming year based on analyst 1-year target prices. (They are tinted gray in the chart below). Thus, the yield-based forecast for these Mid-October dogs was graded by Wall St. Wizards as 40% accurate. Projections were based... Read more